Table 2 Patient characteristics

Sex

male;28 : female;7 (80 %:20 %)

Age

65.7 ± 5.7

Performance status (ECOG)

0

3 (8.6 %)

1

32 (91.4 %)

Histology

Small cell carcinoma

17 (48.6 %)

Adenocarcinoma

12 (34.3 %)^a

Squamous carcinoma

3 (8.6 %)

Pleural mesothelioma

2 (5.7 %)

Large cell carcinoma

1 (2.9 %)

Clinical stage (UICC TNM)

I B

1 (2.9 %)

IIA

2 (5.7 %)

IIB

1 (2.9 %)

IIIA

6 (17.1 %)

IIIB

3 (8.6 %)

IV

21 (60.0 %)

Unknown

1 (2.9 %)

Smoking status

Never

6 (17.1 %)

Ever

11 (31.4 %)

Current

18 (51.4 %)

CDDP dosage (mg/m2)

69.7 ± 8.9

CDDP cumulative dosage (mg/m2)

278.6 ± 63.3

Course

4.1 ± 0.9

CDDP dose reduction (%)

None

21 (60 %)

1 stage reduction

8 (23 %)

2 stage reduction

6 (17 %)

Regimen

CDDP + MTA ± BV

12 (34 %)

CDDP + VP-16

12 (34 %)

CDDP + CPT-11

5 (14 %)

CDDP + GEM

5 (14 %)

CDDP + DTX

1 (4 %)

Hydration volume (mL)

1937 ± 193

Infusion time (hr)

4.8 ± 1.1

Renal function

sCre (mg/dL)

0.7 ± 0.1

BUN (mg/dL)

14.3 ± 3.8

Adjusted eGFR (mL/min)

79.8 ± 9.9